BioCryst Expects To Achieve No Less Than $320M In FY23 Orladeyo Revenue And $1 Billion In Peak Orladeyo Revenue
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals has projected a minimum of $320 million in FY23 revenue from Orladeyo and expects to reach $1 billion in peak Orladeyo revenue.
November 02, 2023 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCryst's revenue forecast for Orladeyo could positively impact its stock price.
BioCryst's projected revenue from Orladeyo is significant. If the company achieves these targets, it could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100